-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Fulcrum Therapeutics, Raises Price Target to $18

Benzinga·12/11/2025 17:47:29
语音播报
Truist Securities analyst Gregory Renza maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and raises the price target from $14 to $18.